Sorafenib is the gold standard therapy for the advanced hepatocellular carcinoma (HCC). No scoring/staging is universally accepted to predict the survival of these patients.
Comparison of prognostic models in advanced hepatocellular carcinoma patients undergoing Sorafenib: A multicenter study
Giannini, Edoardo Giovanni;
2021-01-01
Abstract
Sorafenib is the gold standard therapy for the advanced hepatocellular carcinoma (HCC). No scoring/staging is universally accepted to predict the survival of these patients.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Dig Liver Dis & prognostic models in HCC.pdf
accesso chiuso
Tipologia:
Documento in versione editoriale
Dimensione
1.04 MB
Formato
Adobe PDF
|
1.04 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
